| Generic Name |
Cefixime Capsules |
| Strength |
400mg |
| Packing |
6 Capsules/box |
| Origin |
China |
Value-added services:
Packaging design by our team
Registration service by our team
Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Product name:
cefixime Capsules
Character:
The contents of this product are white or light yellow powder.
Indications:
This product is suitable for the following bacterial infectious diseases introduced by cefixime sensitive Streptococcus (except enterococcus), pneumococcus, gonococcus, Catarrania, Escherichia coli, Klebsiella, Serrella, Proteus and influenzae:
1. Bronchitis, bronchiectasis (when infected), secondary infection of chronic respiratory infections, pneumonia;
2, pyelonephritis, cystitis, gonococcal urethritis;
3, cholecystitis, cholangitis;
4. Scarlet fever;
5. Otitis media and paranasal sinusitis.
Adverse reactions:
Clinical study data showed that the main adverse reactions of this product included gastrointestinal reactions such as diarrhea (0.87%), skin symptoms such as skin rash (0.23%), abnormal clinical examination values (including increased GPT (0.61%), increased GOT (0.45%), and eosinophilia (0.20%). The details are as follows:
1. Serious adverse reactions:
(1) Shock: there are causes of shock (< The possibility of 0.1%), should be closely observed, if there is discomfort, abnormal sensation in the mouth, asthma, dizziness, stool, tinnitus, sweating and other phenomena, should stop the drug administration, take appropriate treatment.
(2) Allergic symptoms: there are allergic symptoms (including dyspnea, systemic flushing, angioneurotic edema, urticaria, etc.) (< The probability of 0.1%) should be closely observed, and if there are abnormalities, the administration should be stopped and appropriate disposal should be taken.
(3) Skin lesions: cutaneous mucocutaneous syndrome (Stevens-Johnson syndrome (0.1%)), toxic epidermal necrosis (Lyell syndrome, < If fever, headache, joint pain, skin or mucous membrane erythema, blisters, skin tension, burning sensation, pain and other symptoms occur, drug administration should be stopped and appropriate treatment should be taken.
(4) Blood disorders: agranulocytosis (< 0.1%, early symptoms: fever, sore throat, headache, fatigue, etc.), hemolytic anemia (< 0.1%, early symptoms: fever, hemoglobinuria, anemia and other symptoms), thrombocytopenia (< 0.1%, early symptoms: spot-like bleeding, purple spots, etc.), etc., and there are also reports of pancytopenia as with other cephalosporin antibiotics, so close observation should be conducted, such as regular examination, etc., when there is an abnormal occurrence, the administration should be stopped and appropriate treatment should be taken.
(5) Renal dysfunction: serious renal dysfunction such as acute renal insufficiency (< Therefore, close observation should be conducted, such as regular examination, etc., if there is an abnormal occurrence, the administration should be stopped and appropriate disposal should be taken.
(6) Colitis: may cause severe colitis with bloody stool, such as pseudomembranous colitis, etc. (< 0.1%). In case of abdominal pain and recurrent diarrhea, the administration should be stopped immediately and appropriate treatment should be taken.
(7) Interstitial pneumonia (symptoms with fever, cough, dyspnea, chest X-ray abnormalities, eosinophilia, etc.) and PIE syndrome (all < If the above symptoms occur, the administration should be stopped and appropriate treatment such as glucocorticoid should be taken.
Pharmacology and toxicology:
Pharmacological effects
This product is the third generation of oral cephalosporin, with a wide antibacterial spectrum, and has antibacterial activity against some Gram-positive and negative bacteria, especially against streptococcus (except enterococcus) and pneumococcus in Gram-positive bacteria, gonococcus, Branham's coccus, Coliform bacteria, Klebsiella, Scharella, Proteus, influenzae and other gram-negative bacteria. The mechanism of action is bactericidal.
This product has strong stability against the β-lactamase produced by various bacteria, and shows superior antibacterial power against the β-lactamase producing bacteria.
The mechanism of action of this product is to prevent the synthesis of bacterial cell walls, and its application point varies according to the species of bacteria, and it has a high affinity with 1 (1a, 1b, 1c) and 3 of penicillin binding proteins (PBP).
antigenicity
The antigenicity of this drug to various animals is the same or slightly weaker than that of cephalexin. This drug does not induce antigenicity, nor does it have immunocross-correlation with cefalexin, cephalox and cefotaxime.
Storage:
Shade, seal, and store in a cool and dark place (not more than 20ºC).
Audited Supplier 
){kind=link}
){kind=link}